Vectorite Biomedical

Vectorite Biomedical Financing Cash Flow

The Net Financing Cash Flow of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 200,000.00 TWD. In the previous year, Net Financing Cash Flow was 118.08 M TWD — a change of -99.83% (lower).

Financing Cash Flow

200,000.00TWD

YoY

-99.83%

Last updated:

Net Financing Cash Flow of Vectorite Biomedical is 2024 200,000.00 TWD. Net Financing Cash Flow of Vectorite Biomedical was 2023 118.08 M TWD. It decreases by -99.83% lower compared to the previous year.

The Vectorite Biomedical Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2015
-4.86 M TWD
Jan 1, 2016
4.86 M TWD
Jan 1, 2017
36.23 M TWD
Jan 1, 2018
4.03 M TWD
Jan 1, 2019
117.27 M TWD
Jan 1, 2020
114.22 M TWD
Jan 1, 2021
118.08 M TWD
Jan 1, 2024
200,000.00 TWD
The Vectorite Biomedical Financing Cash Flow history
YEARFinancing Cash FlowYoY
200,000.00TWD-99.83%
118.08 MTWD+3.37%
114.22 MTWD-2.60%
117.27 MTWD+2,813.47%
4.03 MTWD-88.89%
36.23 MTWD+645.06%
4.86 MTWD-200.02%
-4.86 MTWD-103.25%
149.79 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Net Financing Cash Flow of Vectorite Biomedical is 200,000.00 TWD in 2024.

Net Financing Cash Flow of Vectorite Biomedical changed from 118.08 M TWD to 200,000.00 TWD, representing a -99.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectorite Biomedical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectorite Biomedical